This study is in progress, not accepting new patients

Cytogenetic Studies in Acute Leukemia and Multiple Myeloma

a study on Leukemia Acute Lymphoblastic Leukemia Myelodysplastic Syndrome Multiple Myeloma Acute Myeloid Leukemia Lymphoma

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
Principal Investigator
by Lloyd Damon
Headshot of Lloyd Damon
Lloyd Damon

Description

Summary

Chromosomal analysis or the study of genetic differences in patients previously untreated with AML, ALL, MDS or MM may be helpful in the diagnosis and classification of disease. It may also improve the ability to predict the course of disease and the selection of therapy. Institutions must have either an Alliance-approved cytogeneticist or an agreement from an Alliance-approved main member cytogenetics laboratory to enroll a patient on CALGB 8461. The Alliance Approved Institutional Cytogeneticists list is posted on the Alliance for Clinical Trials in Oncology website.

Official Title

Cytogenetic Studies in Acute Leukemia and Multiple Myeloma: Companion to CALGB Treatment Studies For Previously Untreated Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS) or Multiple Myeloma (MM) Patients

Keywords

Acute Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, Leukemia, Plasma Cell Neoplasms, Preleukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoid Leukemia, Myelodysplastic Syndromes, Acute Disease, cytogenetic analysis

Eligibility

For people ages 18 years and up

  1. Patients from adjuncts are eligible if the Main Member Cytogenetics laboratory has agreed to process samples from that adjunct.
  2. Within one month of registration on CALGB 8461, register onto a CALGB treatment study for previously untreated AML, ALL, MDS, or MM patients.
  3. Simultaneously with registration on CALGB 8461, register patients within the continental United States onto CALGB 9665 (LTB).

Locations

  • UCSF Helen Diller Family Comprehensive Cancer Center
    San Francisco California 94115 United States
  • Camino Medical Group - Treatment Center
    Mountain View California 94040 United States

Lead Scientist at UCSF

  • Lloyd Damon
    Dr. Lloyd Damon is a hematologist and researcher who specializes in blood cancers such as lymphomas and leukemias. Damon studies new treatments for acute myeloid and acute lymphoblastic leukemias. In 1995, he was an early investigator of rituximab, the first monoclonal antibody approved to treat human cancer, specifically lymphoma.

Details

Status
in progress, not accepting new patients
Start Date
Sponsor
Alliance for Clinical Trials in Oncology
ID
NCT00048958
Study Type
Observational
Participants
Expecting 9000 study participants
Last Updated